A5074084071- Opioid Use Disorder Treatment
- Substance Abuse Treatment and Outcomes
- Prenatal Substance Exposure Effects
- Treatment of Major Depression
- Non-Invasive Vital Sign Monitoring
- Pain Management and Opioid Use
- Reproductive Biology and Fertility
- Childhood Cancer Survivors' Quality of Life
- Cannabis and Cannabinoid Research
- Neonatal and fetal brain pathology
- Acute Myeloid Leukemia Research
- Ovarian function and disorders
- Acute Lymphoblastic Leukemia research
- Gynecological conditions and treatments
- Optical Imaging and Spectroscopy Techniques
Centre Hospitalier Universitaire Sainte-Justine
2021-2024
Centre Hospitalier de l’Université de Montréal
2022
University of Toronto
2022
Objective: Extensive exposure to prescription-type opioids has resulted in major harm worldwide, calling for better-adapted approaches opioid agonist therapy. The authors aimed determine whether flexible take-home buprenorphine/naloxone is as effective supervised methadone reducing use consumers with disorder. Methods: This seven-site, pan-Canadian, 24-week, pragmatic, open-label, noninferiority, two-arm parallel randomized controlled trial involved treatment-seeking adults Participants were...
Conflictual evidence exists regarding the effects of cannabis use on outcomes opioid agonist therapy (OAT). In this exploratory analysis, we examined effect recent use, craving, and withdrawal symptoms, in individuals participating a trial comparing flexible buprenorphine/naloxone (BUP/NX) take-home dosing model to witnessed ingestion methadone. We analyzed data from multi-centric, pragmatic, 24-week, open label, randomized controlled with prescription-type disorder (n = 272), randomly...
Objective This study aimed to evaluate the effectiveness of flexible take-home dosing buprenorphine/naloxone (BUP/NX) and methadone standard model care in reducing depressive symptoms people with prescription-type opioid use disorder (POUD). trial also evaluated whether improvements were mediated by use. Methods Analyzed data came from OPTIMA (clinicaltrials.gov identifier: NCT03033732), a pragmatic randomised controlled comparing BUP/NX for POUD. A total 272 participants recruited four...
To evaluate the impact of depressive symptom severity on opioid use and treatment retention in individuals with prescription-type disorder (POUD).
Craving reduction is an important target in the treatment of prescription-type opioid use disorder (POUD). In this exploratory analysis, we compared effectiveness BUP/NX flexible model care relative to methadone for craving individuals with POUD. We analyzed data from a multicentric, pragmatic, 24-week open-label randomized controlled trial conducted participants POUD (N = 272) who were randomly assigned take-home dosing (n 138) or standard closely supervised 134). Treatments prescribed and...
Infants born at 29-36 weeks gestational age (GA) are risk of experiencing neurodevelopmental challenges. We hypothesize that cerebral hemodynamics and oxygen metabolism measured by bedside optical brain monitoring potential biomarkers development associated with neurological examination term-equivalent (TEA). Preterm infants (N = 133) GA admitted in the neonatal intensive care unit were enrolled this prospective cohort study. Combined frequency-domain near infrared spectroscopy (FDNIRS)...
The epidemiology of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype (MPAL) in Canada is unknown. main objective was to describe the prevalence, prognostic factors, outcomes three rare high-risk ALL subtypes Canada. This a retrospective study using Cancer Young People-Canada (CYP-C) database. Event-free survival (EFS) overall (OS) were described by Kaplan–Meier method compared log-rank test. Among 2626 children aged 0–14 years diagnosed with B-cell (B-ALL)...